Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials-Reference-Cited by-同舟云学术

Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials

Published:2018-10 Issue:5 Volume:28 Page:371-379
ISSN:0960-8931
Container-title:Melanoma Research
language:en
Short-container-title:

Author:

Menshawy Amr,Eltonob Abdelrahman A.,Barkat Sarah A.,Ghanem Ahmed,Mniesy Mahmoud M.,Mohamed Ishak,Abdel-Maboud Mohamed,Mattar Omar M.,Elfil Mohamed,Bahbah Eshak I.,Elgebaly Ahmed

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Dermatology,Oncology

Reference32 articles.

1. A landscape of driver mutations in melanoma;Hodis;Cell,2012

2. Nivolumab in the treatment of malignant melanoma : review of the literature;Hara;Onco Targets Ther,2015

3. Letter to the Editor Expression of AID in malignant melanoma with BRAF V600E mutation;Okura;Exp Dermatol,2014

4. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial;Robert;The Lancet,2014

5. PD-1 as a potential target in cancer therapy;Mcdermott;Cancer Med,2013

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PD-1 and CTLA-4 inhibitors in combination vs. alone for the treatment of advanced melanoma: A systematic review and meta-analysis;Medicine;2022-10-14

2. Primary adrenal melanoma;ANZ Journal of Surgery;2022-08-25

3. Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis;Cancer Cell International;2021-08-14

4. Neutrophils in cancer, a love‐hate affair;The FEBS Journal;2021-05-17

5. The efficacy and safety of Nivolumab combined with Ipilimumab in the immunotherapy of cancer: a meta-analysis;Immunopharmacology and Immunotoxicology;2021-05-04